1. |
Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J, 2017, 7(6): e577.
|
2. |
Brown PA, Wieduwilt M, Logan A, et al. Guidelines insights: acute lymphoblastic leukemia, version 1. 2019. J Natl Compr Canc Netw, 2019, 17(5): 414-423.
|
3. |
乔荣华. 南京某三甲医院白血病患者首次住院费用分析. 南京: 东南大学, 2017.
|
4. |
中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版). 中华血液学杂志, 2016, 37(10): 837-845.
|
5. |
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med, 2016, 375(8): 740-753.
|
6. |
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer, 2019, 125(14): 2474-2487.
|
7. |
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med, 2017, 376(9): 836-847.
|
8. |
Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018, 378(5): 439-448.
|
9. |
Degeling K, Vu M, Koffijberg H, et al. Health economic models for metastatic colorectal cancer: a methodological review. Pharmacoeconomics, 2020, 38(7): 683-713.
|
10. |
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 2013, 16(2): 231-250.
|
11. |
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care, 2013, 29(2): 117-122.
|
12. |
Sarkar RR, Gloude NJ, Schiff D, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst, 2019, 111(7): 719-726.
|
13. |
Thielen FW, van Dongen-Leunis A, Arons AMM, et al. Cost-effectiveness of anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. Eur J Haematol, 2020, 105(2): 203-215.
|
14. |
Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr, 2018, 172(12): 1161-1168.
|
15. |
Lee TY, Chen HY, Chen TY, et al. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system. Eur J Health Econ, 2020, 21(7): 1105-1116.
|
16. |
Ribera Santasusana JM, de Andrés Saldaña A, García-Muñoz N, et al. Cost-effectiveness analysis of tisagenlecleucel in the treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in children and young adults in Spain. Clinicoecon Outcomes Res, 2020, 12: 253-264.
|
17. |
Delea TE, Zhang X, Amdahl J, et al. Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Pharmacoeconomics, 2019, 37(9): 1177-1193.
|
18. |
Lin JK, Lerman BJ, Barnes JI, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol, 2018, 36(32): 3192-3202.
|
19. |
Furzer J, Gupta S, Nathan PC, et al. Cost-effectiveness of tisagenlecleucel vs standard care in high-risk relapsed pediatric acute lymphoblastic leukemia in Canada. JAMA Oncol, 2020, 6(3): 393-401.
|
20. |
Delea TE, Amdahl J, Boyko D, et al. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ, 2017, 20(9): 911-922.
|
21. |
Wakase S, Teshima T, Zhang J, et al. Cost-effectiveness analysis of tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia in Japan. Transplant Cell Ther, 2021, 27(3): 241.e1-241.e11.
|
22. |
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med, 2015, 373(16): 1541-1552.
|
23. |
刘国恩. 中国药物经济学评价指南. 北京: 中国市场出版社, 2020.
|
24. |
邵荣杰, 唐文熙, 马爱霞. 分区生存模型在药物经济学评价中的应用. 中国卫生经济, 2019, 38(9): 60-63.
|
25. |
ClinicalTrials. gov. Phase I/IIA study of CART19 cells for patients with chemotherapy resistant or refractory CD19+ leukemia and lymphoma. Available at: https://clinicaltrials.gov/ct2/show/NCT01626495.
|
26. |
ClinicalTrials.gov. Study of efficacy and safety of CTL019 in pediatric ALL patients. Available at: https://clinicaltrials.gov/ct2/show/NCT02228096.
|
27. |
Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood, 2011, 118(23): 6043-6049.
|
28. |
Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol, 2006, 24(12): 1917-1923.
|
29. |
von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol, 2016, 34(36): 4381-4389.
|
30. |
Sung L, Buckstein R, Doyle JJ, et al. Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis. Cancer, 2003, 97(3): 592-600.
|
31. |
Kwon J, Kim SW, Ungar WJ, et al. A systematic review and meta-analysis of childhood health utilities. Med Decis Making, 2018, 38(3): 277-305.
|
32. |
Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer, 2014.
|
33. |
Kelly MJ, Pauker SG, Parsons SK. Using nonrandomized studies to inform complex clinical decisions: the thorny issue of cranial radiation therapy for T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer, 2015, 62(5): 790-797.
|
34. |
Martin PJ, Counts GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol, 2010, 28(6): 1011-1016.
|
35. |
Kurosawa S, Yamaguchi T, Mori T, et al. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant, 2015, 50(9): 1241-1249.
|
36. |
Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making, 2006, 26(4): 410-420.
|
37. |
Crotta A, Zhang J, Keir C. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Curr Med Res Opin, 2018, 34(3): 435-440.
|
38. |
Portwine C, Rae C, Davis J, et al. Health-related quality of life in survivors of high-risk neuroblastoma after stem cell transplant: a national population-based perspective. Pediatr Blood Cancer, 2016, 63(9): 1615-1621.
|
39. |
Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology Am Soc Hematol Educ Program, 2014, 2014(1): 559-564.
|
40. |
Miano M, Pistorio A, Putti MC, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. Leuk Lymphoma, 2012, 53(9): 1693-1698.
|
41. |
Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol, 2009, 147(3): 371-378.
|
42. |
Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making, 2012, 32(5): 667-677.
|
43. |
费正洋, 张雪珂, 王樱澄, 等. PD-1/PD-L1抑制剂治疗非小细胞肺癌的成本-效用分析方法学系统评价. 中国药房, 2021, 32(20): 2499-2508.
|